Evaluation of TQA3526 single-center, randomized, double-blind, placebo-controlled, multi-dose, single-, multiple-dose, and pharmacokinetic Phase Ia clinical trial in healthy subjects
Latest Information Update: 15 Oct 2020
At a glance
- Drugs TQA 3526 (Primary)
- Indications Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Focus First in man; Pharmacodynamics; Pharmacokinetics
- 29 Aug 2020 Results assessing treatment emergent adverse events, pharmacokinetic and pharmacodynamics profiles presented at The International Liver Congress 2020
- 01 Jul 2019 Status changed to active, no longer recruiting.
- 01 Jul 2019 New trial record